All In Biotech

Drug Trial Radar · NCT07288112

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Apr 6, 2026

Primary completion

Jan 2031

Study completion Jan 2033

Sponsor

Lead sponsor
Diakonos Oncology CorporationIndustry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells. The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the treatment regimen. All participants will: * Undergo a leukapheresis collection (take filgrastim subcutaneously x 5 doses, if clinically necessary, leading up to collection) * Receive two doses of DOC1021 under image guidance 2 weeks apart * Receive subcutaneous pIFN injections weekly for a total of 4 doses in parallel with the DOC1021 injections * Undergo an optional image-guided perinodal DOC1021 booster injection approximately 6 months after the first DOC1021 dose along with additional subcutaneous pIFN injections at time of the booster and the subsequent week for a total of 2 pIFN doses * Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive optional treatment with anti-PD1 agents

Conditions

  • Refractory Melanoma

Interventions

  • DOC1021Biological

    Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method

  • Tumor resectionProcedure

    Tumor resection or biopsy

  • pIFN (peginterferon alfa-2a)Drug

    pIFN 180 mcg subcutaneously every week for 4 total doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: To evaluate the number of dose limiting toxicities reportedTime frame: From time of first DOC1021 dose administration to 6 weeks later
  2. Phase II: To evaluate the objective response rate (ORR) as the proportion of patients with a confirmed complete response (CR) or partial response (PR) to treatment, as per RECIST 1.1 criteriaTime frame: 5 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Arizona State University-Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • Massachusetts General Hospital Cancer Institute

    Boston, Massachusetts · Recruiting

  • Atlantic Health

    Morristown, New Jersey · Recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • UT Southwestern

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.